Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001753926-25-000202
Filing Date
2025-02-10
Accepted
2025-02-10 21:02:32
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10690
2 EXHIBIT 1 g084690_ex-1.htm EX-1 11897
  Complete submission text file 0001753926-25-000202.txt   24392
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92289 | Film No.: 25607397
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 140 BROADWAY 38TH FLOOR NEW YORK NY 10005
Business Address 874 WALKER ROAD SUITE C DOVER DE 19904 (646) 845-0040
3i, LP (Filed by) CIK: 0001841619 (see all company filings)

EIN.: 843800874 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G